Department of Error (DOI:10.1016/S0140-6736(08)61242-8);Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

The Lancet

Volumn 372, Issue 9644, 2008, Pages 1174-1183

  Yusuf, Salim ^a   Teo, K ^a,a,a   Anderson, C ^a   Pogue, J ^a   Dyal, L ^a   Copland, I ^a   Schumacher, H ^a   Dagenais, G ^a   Sleight, P ^a   Ramos, B ^a   Richardson, L ^a,a   Murphy, J ^a,a   Haehl, M ^a   Hilbrich, L ^a   Svaerd, R ^a   Martin, K ^a   Murwin, D ^a   Meinicke, T ^a   Schlosser, A ^a   Schmidt, G ^a   Creek, R ^a   Distel, M ^a   Aubert, B ^a   Schmieder, R ^a,a   Unger, T ^a   Asmar, R ^a   Mancia, G ^a   Diaz, R ^a   Paolasso, E ^a   Piegas, L ^a,a   Avezum, A ^a   Cardona Munoz, E ^a,a   Probstfield, J ^a,a   Weber, M ^a,a   Young, J ^a,a   Fagard, R ^a,a   Jansky, P ^a   Mallion, J ^a,a   Mann, J ^a   Bohm M ^a,a,a   Eber, B ^a   Karatzas, N B ^a   Keltai, M ^a   Trimarco, B ^a,a   Verdecchia, P ^a,a   Maggioni, A ^a   Verheugt, F W A ^a,a   Holwerda, N J ^a   Ceremuzynski, L ^a,a   Budaj, A ^a   Ferreira, R ^a,a   Chazova, I ^a,a   Ryden L ^a,a   Svendsen, T L ^a,a   Metsarinne K ^a,a   Dickstein, K ^a,a   Fodor, G ^a   Commerford, P ^a,a   Redon, J ^a   Luescher, T R ^a   Oto, A ^a,a   Binbrek, A ^a   Parkhomenko, A ^a   Jennings, G ^a   Liu, L S ^a   Yu, C M ^a,a   Dans, A L ^a,a   Shah, R ^a   Kim, J H ^a,a   Chen, J H ^a   Chaithiraphan, S ^a,a   Cairns, J ^a   Wilhelmsen, L ^a   Chalmers, J ^a   Wittes, J ^a   Gent, M ^a   Hennekens, C H ^a   Anderson, N ^a   Yusoff, K ^a,a   Auger, P ^a,a   Bernstein, V ^a,a   Lonn, E ^a,a   Panju, A ^a   Anand, I ^a   Bigger, J T ^a   Linz, P ^a   Healey, J ^a   Held, C ^a   McGorrian, C ^a   Rokoss, M ^a   Villar, J ^a   Dans, A ^a   Yusuf, S ^a,a   McDonald, A ^a   Schweitzer, D ^a   Cunningham, J ^a   Wagan, E ^a   Boland, T ^a   Westfall, L ^a   Gulliver, N ^a   Oliveira, R ^a   McLean Price, C ^a   Kotlan, S ^a   Tosto, F ^a   Afzal, R ^a   Zhao, F ^a   Ahuad Guerrero, R A ^a   Amuchastegui, M ^a   Baglivo, H P ^a   Bendersky, M ^a   Bono, J ^a   Bustos, B ^a   Caccavo, A ^a   Cartasegna, L R ^a   Castellanos, C R ^a   Cipullo, M ^a   Cuneo, C A ^a   Fuselli, J J ^a   Guaymas, G J ^a   Hasbani, E ^a   Hominal, M A ^a   Humphreys, J D ^a   Killinger, C R ^a   Kuschnir, E ^a   Majul, C R ^a   Marzetti, E M ^a   Nordaby, R ^a   Orlandini, A D ^a   Paez, O B L ^a   Piasentin, J A ^a   Pomposiello, J C ^a   Resk, J H ^a   Rodriguez G M ^a   Said Nisi, J ^a   Sala, J M ^a   Sanchez, R A ^a   Schygiel, P O ^a   Serra, C ^a   Vico, M L ^a   Jennings, G L R ^a   Amerena, J V ^a   Arnolda, L F ^a   Aylward, P E ^a   Bladin, C F ^a   Chambers, B R ^a   Crimmins, D S ^a   Cross, D B ^a   Davies, L ^a   Davis, S M ^a   Eccleston, D S ^a   Frayne, J H ^a   Herkes, G K ^a   Hill, A T ^a   Jeffery, I M ^a   Karrasch, J A ^a   Marwick, T H ^a   Parsons, M W ^a   Rees, D M ^a   Russell, A ^a   Schwartz, R ^a   Singh, B B ^a   Thompson, P L ^a   Waites, J H ^a   Walsh, W F ^a   Watts, R W ^a   Whelan, A P ^a   Eber, B E ^a   Bonelli, J ^a   Dolliner, P ^a   Hohenecker, J ^a   Steurer, G ^a   Weber, T ^a   Weihs, W ^a   Bekaert, I ^a   Brohet, C ^a   Crasset, V ^a   Degaute, J P ^a   Dendale, P ^a   Dujardin, K ^a   Elshot, S ^a   Heyndrickx, G ^a   Lesseliers, H ^a   Quinonez, M ^a   Van Mieghem, W ^a   Vanhooren, G ^a   Vervoort, G ^a   Wollaert, B ^a   Abrantes, J A M ^a   Armaganijan, D ^a   Bodanese, L C ^a   Carvalho, A C ^a   Coutinho, M ^a   Esteves, J P ^a   Fichino, M Z S ^a   Franco, R J S ^a   Leaes P E ^a   Maia, L N ^a   Marin Neto, J A ^a   Marino, R L ^a   Mion, D ^a   Oigman, W ^a   Pedrosa, R C ^a   Pelloso, E A ^a   Polanczyk, C A ^a   Rabelo, A ^a   Rassi, S ^a   Reis, G ^a   Ribeiro, A B ^a   Ribeiro, J M ^a   Rocha, J C ^a   Rossi, F H ^a   Rossi, P R F ^a   Santos, R D ^a   Saraiva, J F K ^a   Tarastchuk, J C E ^a   Vidotti, M H ^a   Abramson, B ^a   Arnold, J M ^a   Ashton, T ^a   Bata, I ^a   Bayly, K ^a   Beauchef, J ^a   Belanger A ^a   Bhargava, R ^a   Booth, A W ^a   Borts, D ^a   Bose, S ^a   Boulianne, M ^a   Bozek, B ^a   Cameron, M ^a   Chan, Y K ^a   Constance, C ^a   Costi, P ^a   Douketis, J ^a   Fell, D ^a   Giannoccaro, J P ^a   Glanz, A ^a   Gosselin, G ^a   Gould, D ^a   Goulet, S ^a   Gupta, M K ^a   Gyenes, G ^a   Heath, J W ^a   Hiscock, J G ^a   Hoag, G ^a   Honos, G ^a   Imrie, J ^a   Kuritzky, R ^a   Lai, C ^a   Lalani, A V ^a   Lamy, A ^a   LeBouthillier, P ^a   Lubelsky, B ^a   Mackey, A ^a   Meunier, M ^a   Milot, A ^a   Nawaz, S ^a   Pilon, C ^a   Pilon, D ^a   Polasek, P ^a   Proulx, G ^a   Rebane, T ^a   Ricci, A J ^a   Sabbah, E ^a   Savard, D ^a   Sharma, N K ^a   Shu, D ^a   Sigal, R J ^a   St Hilaire, R ^a   St Maurice, F ^a   Starra, R ^a   Sussex, B ^a   Talbot, P ^a   Tan, K W ^a   To, T B ^a   Tobe, S W ^a   Tytus, R ^a   Vexler, R ^a   Whitsitt, P ^a   Liu, L ^a   Bai, X ^a   Cao, S ^a   Chen, X ^a   Dong, L ^a   Feng, J ^a   Fu, S ^a   Gong, L ^a   He, Z ^a   Jiang, Y ^a   Li, J ^a   Li, L ^a   Li, Q ^a   Li, X ^a   Liao, Y ^a   Lu, F ^a   Lu, Z ^a   Ma, S ^a   Niu, F ^a   Pan, C ^a   Qian, F ^a   Sun, G ^a   Sun, M ^a   Sun, N ^a   Wang, L ^a   Wang, S ^a   Wang, Y ^a   Wu, Z ^a   Yan, X ^a   Yang, H ^a   Yang, X ^a   Yuan, S ^a   Zhang, C ^a   Zhang, F ^a   Zhang, S ^a   Zhang, T ^a   Zhao, D ^a   Zheng, B ^a   Zhou, S ^a   Zhu, J ^a   Zhu, S ^a   Jansky P ^a   Dedek, V ^a   Dvorak J ^a   Holaj, R ^a   Kotous J ^a   Nemcova, H ^a   Pech, M ^a   Pederzoliova E ^a   Polak M ^a   Povolny J ^a   Smetana, K ^a   Spac J ^a   Gotzsche L ^a   Juhl, H F ^a   Koelendorf, K ^a   Lund, P ^a   Nielsen, E S ^a   Pedersen, F ^a   Rasmussen, L H ^a   Rasmussen, S L ^a   Thygesen, K ^a   Tuxen, C ^a   Antikainen, R ^a   Jaaskivi M ^a   Kantola, I ^a   Kastarinen, M ^a   Kohonen Jalonen, P ^a   Koistinen, A ^a   Lehmus, E ^a   Nuuttila, R ^a   Tuomilehto, J ^a   Tuominen, M L ^a   Abenhaim, N ^a   Allix, J ^a   Boucher, L ^a   Bourgoin, M ^a   Boye, A ^a   Breton, N ^a   Cadinot, D ^a   Campagne, A ^a   Churet, J ^a   Constantin, G ^a   De Sainte Lorette, E ^a   El Sawy, A ^a   Farhat, S ^a   Lacoin, F ^a   Magnani, C ^a   Pineau Valenciennes, D ^a   Pithon, M ^a   Queguiner A ^a   Sicard, J ^a   Taminau, D ^a   Vilarem, H ^a   Vogel, J Y ^a   Brado, B ^a   Claus, G ^a   Dietz, U ^a   Griebenow, R ^a   Haak, T ^a   Hahn, K ^a   Hampel, R ^a   Holle, G ^a   Horacek, T ^a   Jordan, J ^a   Klein, C ^a   Motz, W ^a   Muenzel, T ^a   Minnich, J ^a   Nebelsieck, H ^a   Rybak, K ^a   Samer, H ^a   Schaefer, T ^a   Scholze, J ^a   Schwaab, B ^a   Sechtem, U ^a   Sehnert, W ^a   Steinhagen Thiessen, E ^a   Stenzel, G ^a   Trenkwalder, P ^a   Wedler, B ^a   Zippel, J ^a   Karatzas, N ^a   Achimastos, A ^a   Efstratopoulos, A ^a   Elisaf, M ^a   Georgakopoulos, N D ^a   Louridas, G ^a   Pyrgakis, V ^a   Symeonidis, D ^a   Vogiatzis, I ^a   Voyaki, S ^a   Chan, C K H ^a   Chan, W K ^a   Lam, L ^a   Lau, C P ^a   Lau, Y K ^a   Sanderson, J E ^a   Wong, K S ^a   Yue, C S ^a   Czuriga, I ^a   Edes I ^a   Farsang, C S ^a   Kalina, A ^a   Karlocai K ^a   Keltai, K ^a   Kozma, M ^a   Laszlo Z ^a   Papp, A ^a   Polak G Y ^a   Preda I ^a   Ronaszeki A ^a   Sereg, M ^a   Simon, K ^a   Szegedi, J ^a   Szilagyi H ^a   Toth K ^a   Vandorfi G Y ^a   Vertes A ^a   Crean, P A ^a   Maher, V M G ^a   Stanton, A V ^a   Achilli, A ^a   Agabiti Rosei, E ^a   Ambrosio, G B ^a   Bentivoglio, M ^a   Branzi, A ^a   Chersevani, D ^a   Chiariello, M ^a   Cirrincione, V ^a   Dembech, C ^a   Ferrari, R ^a   Gattobigio, R ^a   Giovannini, E ^a   Lauro, R ^a   Lembo, G ^a   Moretti, L ^a   Pancaldi, L ^a   Pede, S ^a   Pettinati, G ^a   Reboldi, G ^a   Ricci, R ^a   Rosiello, G ^a   Rozza, F ^a   Sardone, M G ^a   Tavazzi, L ^a   Terrosu, P ^a   Venco, A ^a   Vetrano, A ^a   Volpe, M ^a   Shah, R P ^a   Singaraveloo, M ^a   Wan Ahmad, W A ^a   Yusof, Z ^a   Zambahari, R ^a   Alcocer, L ^a   Arriaga Nava, R ^a   Bricio Ramirez R I ^a   De La Pena Topete G ^a   Elizondo Sifuentes, L A ^a   Hernandez Garcia H R ^a   Macias Islas M A ^a   Martinez Lugo, C ^a   Noriega Arellano, J A ^a   Pascoe Gonzalez, S ^a   Olvera Ruiz, R ^a   Parra Carrillo, J Z ^a   Velasco Sanchez G ^a   Vidrio Velasquez M ^a   Boermans, A J M ^a   Buiks, C P ^a   de Graaf, J J ^a   Eefting, F D ^a   Michels, H R ^a   Poldermans, D ^a   Schrijver, G ^a   Sedney, M I ^a   Slagboom, T ^a   Smilde, J G ^a   Storms, G E M G ^a   van Bergen, P F M M ^a   van Doesburg, G J M ^a   van Kempen, L H J ^a   van Mierlo, H F C M ^a   Veerman, A ^a   Vermetten, F A A M ^a   Willems, F F ^a   Doughty, R N ^a   Friedlander, D H ^a   Lainchbury, J G ^a   Luke, R A ^a   Nairn, P L ^a   Peek, D ^a   Richards, A M ^a   Singh, G P ^a   White, H D ^a   Wong, S P ^a   Lier, J O ^a   Otterstad, J E ^a   Ronnevik P K ^a   Skeie, S ^a   Abola, M T B ^a   dela Vega, S A F ^a   Gurango, J A L ^a   Punzalan, F E R ^a   Roxas, A A ^a   Tumanan Mendoza, B A ^a   Binio, Z ^a   Bronisz, M ^a   Buszman, P ^a   Czerski, T ^a   Dalkowski, M ^a   Gessek, J ^a   Gieroba, A ^a   Janik, K ^a   Janion, M ^a   Kawka Urbanek, T ^a   Klabisz, R ^a   Krauze Wielicka, M ^a   Malinowski, S ^a   Miekus, P ^a   Mormul, J ^a   Ogorek, M ^a   Opolski, G ^a   Skura, M ^a   Szpajer, M ^a   Tendera, M ^a   Waszyrowski, T ^a   Wierzchowiecki, M ^a   Zalska, B ^a   Correia, C ^a   Cunha, L ^a   Ferro, J M ^a   Gama Ribeiro, V ^a   Marques da Silva, P ^a   Oliveira Carrageta, M ^a   Sa E ^a   Veloso Gomes, M ^a   Ageev, F ^a   Belenkov, Y ^a   Ivleva, A ^a   Karpov, Y ^a   Shestakova, M ^a   Shlyakhto, E ^a   Shustov, S ^a   Sidorenko, B ^a   Chen, C P L H ^a   Kwok, B ^a   Dukat A ^a   Gonsorcik J ^a   Hranai, M ^a   Pella, D ^a   Ruffini, L ^a   Rybar, R ^a   Brown, B ^a   Dalby, A J ^a   Gibson, G J ^a   Herbst, L ^a   King, J ^a   Klug, E ^a   Middle, M ^a   Naidoo, D P ^a   Podgorski, G ^a   Pretorius, M ^a   Ranjith, N ^a   Silwa Hahnle, K ^a   Theron, H ^a   Chae, S C ^a   Chung, N S ^a   Hong, K P ^a   Jeong, M H ^a   Kang, H J ^a   Kim, J J ^a   Kim, M H ^a   Seo, H S ^a   Shin, E K ^a   Redon J ^a   Barrios, V ^a   Calvo, C ^a   Campos, M M ^a   De Teresa, E ^a   Forner, M J ^a   Galve, E ^a   Gil Extremera, B ^a   Gonzalez Albarran, O ^a   Martell, N ^a   Mazon P ^a   Munoz J ^a   Ruilope, L M ^a   Ruiz, J ^a   Vinyoles, E ^a   Alvang A ^a   Bostrom P A ^a   Dellborg, M ^a   Ericsson, U B ^a   Herlitz, J ^a   Juhlin, T ^a   Pedersen, K ^a   Strang B ^a   Sundqvist, B ^a   Tengmark, B O ^a   Ulvenstam, G ^a   Westerdahl, B ^a   Dubach, P ^a   Moccetti, T ^a   Noll, G ^a   Schlapfer H ^a   Weber, K ^a   Chao, T H ^a   Chen, C Y ^a   Cheng, J J ^a   Chiou, H C ^a   Fu, M ^a   Lai, W T ^a   Liu, P Y ^a   Tsai, C D ^a   Yeh, P S ^a   Chantadansuwan, T ^a   Jirasirirojanakorn, K ^a   Krittayaphong, R ^a   Laothavorn, P ^a   Mahanonda, N ^a   Sitthisook, S ^a   Tanomsup, S ^a   Tansuphaswadikul, S ^a   Tatsanavivat, P ^a   Caglar, N ^a   Ergin, A ^a   Oguz, A ^a   Ongen, Z ^a   Sansoy, V ^a   Tetiker, T ^a   Usal, A ^a   Amosova, E ^a   Dykun, Y ^a   Dzyak, G ^a   Grishyna, O ^a   Kononenko, L ^a   Kovalenko, V ^a   Netyazhenko, V ^a   Pertseva, T ^a   Sirenko, Y ^a   Binbrek, A S ^a   Al Hatou, E ^a   Al Madhi, S ^a   Al Sousi, A A S ^a   Alomairi, M ^a   Radaideh, G ^a   Adgey, A A J ^a   Barer, D H ^a   Barnett, A H ^a   Bridges, A B ^a   Cowie, A S ^a   Cruickshank, J K ^a   De Belder, A J ^a   Donnelly, R ^a   Francis, C M ^a   Fuentealba Melo, P ^a   Gough, N ^a   Jackson, P R ^a   Jackson, S H D ^a   McEneaney, D J ^a   Moriarty, A J ^a   Murdoch, D L ^a   O'Hare J P ^a   Penny, W J ^a   Reid, C J ^a   Vora, J P ^a   Adler, F M ^a   Anand, I S ^a   Anderson, J L ^a   Aponte Pagan J S ^a   Basile, J N ^a   Bass, P F ^a   Brautigam, D F ^a   Carr, A A ^a   Chinn, J ^a   Chiu, D ^a   Cho, N R ^a   Ciocon, J O ^a   Colon Ortiz P J ^a   Cruz, J B ^a   Dachman, W D ^a   Dorfman, S G ^a   Drummond, W ^a   East, C ^a   Eelani, F ^a   Ellison, H S ^a   Felicetta, J V ^a   Force, R W ^a   Goldberg, M C ^a   Goldman, S G ^a   Gomez Adrover, R ^a   Goss, S L ^a   Graham, S P ^a   Granger, C B ^a   Greenspan, M M ^a   Grimm, R H ^a   Habib, G B ^a   Hart, P D ^a   Hartney, T J ^a   Henriquez, M A ^a   Holland, J J ^a   Hoogwerf, B J ^a   Hossfeld, M ^a   Hyman, D ^a   Jacobson, A K ^a   Jelley, M J ^a   Jones, T V ^a   Kaplan, R A ^a   Karalis, D G ^a   Katz, L A ^a   Khan, M ^a   Kipperman, R M ^a   Kozinn, M J ^a   Lader, E W ^a   Landau, C ^a   Lewis, S J ^a   Liang, C S ^a   Linz, P E ^a   Lo, T S ^a   Lopez Arostegui, F ^a   McGuire, D K ^a   Mercando, A D ^a   Mersey, J H ^a   Narayan, P ^a   Oparil, S ^a   Padhiar, D N ^a   Phillips, A L ^a   Prisant, L M ^a   Qureshi, N ^a   Randall, R R ^a   Retta, T M ^a   Rizvi, M D ^a   Saklayen, M G ^a   Sastrasinh, S ^a   Savani, I K ^a   Schlau, A ^a   Schultz, H S ^a   Schweiger, M J ^a   Sosa Padilla, M ^a   Stuver, T P ^a   Subich, D C ^a   Swagler, W A ^a   Taitano, M ^a   Tavarez Valle, J A ^a   Taylor, E M ^a   Wickemeyer, W J ^a   Wiegmann, T B ^a   Zhao, X Q ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TELMISARTAN; TICLOPIDINE;

ADULT; AGED; ARTICLE; AUTOMATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STROKE; SYNCOPE; TREATMENT OUTCOME;

EID: 53049109468     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61586-X     Document Type: Erratum

References (33)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
2. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
3. Dagenais G.R., Pogue J., Fox K., Simoons M.L., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588
4. Bart B.A., Ertl G., Held P., et al., for the SPICE Investigators. Contemporary management of patients with left ventricular systolic dysfunction: results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry. Eur Heart J 20 (1999) 1182-1190
5. McDowell S.E., Coleman J.J., and Ferner R.E. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332 (2006) 1177-1181
6. Pfeffer M.A., McMurray J.J.V., Velasquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
7. ONTARGET Study Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
8. Granger C.B., McMurray J.J.V., Yusuf S., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet 362 (2003) 772-776
9. Maggioni A.P., Anand I., Gottlieb S.O., et al., for the Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 (2002) 1414-1421
10. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
11. Teo K., Yusuf S., Sleight P., et al., for the ONTARGET/TRANSCEND Investigators. Rationale, design and baseline characteristics of two large, simple randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
12. Patel A; ADVANCE Collaborative Group, MacMahon S., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
13. Cox D.R. Regression models and life-tables. J R Stat Soc 34 (1972) 187-220
14. Yusuf S., Diener H.C., Sacco R.L., et al. Randomized trial of early telmisartan therapy to prevent recurrent strokes and major vascular events among 20 000 individuals with previous stroke. N Engl J Med (2008) 10.1056/NEJMoa0804593 published online Aug 27.
15. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
16. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35 (1977) 1-39
17. Arnold J., Yusuf S., Young J., et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 107 (2003) 1284-1309
18. The Prevention of Events with Angiotensin-Converting-Enzyme (PEACE) Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
19. Fox K.M., and for the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
20. Julius S., Kjeldsen S.E., Weber M., et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
22. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
23. Verma S., and Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 329 (2004) 1248-1249
24. Demers C., McMurray J.J., Swedberg K., et al., for the CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294 (2005) 1794-1798
25. Turnbull F., and for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
26. Baigent C., Keech A., Kearney P.M., et al., for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
27. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., and Cobbe S.M. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007) 1477-1486
28. Jong P., Yusuf S., Rousseau M.F., Ahn S.A., and Bangdiwala S.I. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361 (2003) 1843-1848
29. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
30. Yusuf S., Gerstein H., Hoogwerf B., et al., for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
31. Yusuf S., Ostergren J.B., Gerstein H.C., et al., for the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112 (2005) 48-53
32. Lindholm L.H., Ibsen H., Dahlöf B., et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
33. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 (2000) 1967-1975